DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetesAugust 31, 2020Heart FailureDiabetes
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit solidifies class effectsAugust 30, 2020Heart FailureDiabetes
Vitamin D pearlsAugust 28, 2020Preventive CareCOVID-19 UpdatesLipid DisordersHypertensionPediatricsDiabetes
Guidance covers glycemia in dexamethasone-treated COVID-19 patientsAugust 10, 2020DiabetesCOVID-19 Updates
Cleaner data confirm severe COVID-19 link to diabetes, hypertensionJuly 27, 2020DiabetesHypertensionCOVID-19 Updates
SGLT2 inhibitors, developed for T2D, now ‘belong to cardiologists and nephrologists’July 16, 2020DiabetesHeart FailureHypertension
